NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
Clinical Trials
20 trialsNCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT02246127 2025-05-11
SEQTOR
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01668784 2022-08-09
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Bristol-Myers Squibb
Phase 3 Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT03176238 2020-04-07
EVEREXES
Novartis
Phase 3 Completed
NCT01198158 2019-03-06
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT01713946 2018-11-07
EXIST-3
Novartis
Phase 3 Completed
NCT00863655 2017-05-02
BOLERO-2
Novartis
Phase 3 Completed
NCT01007942 2017-04-05
BOLERO-3
Novartis
Phase 3 Completed
NCT01035229 2016-09-22
EVOLVE-1
Novartis
Phase 3 Completed
NCT00789828 2016-02-03
EXIST-1
Novartis
Phase 3 Completed
NCT00879333 2015-11-03
GRANITE-1
Novartis
Phase 3 Completed
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT00410124 2013-01-15
RECORD-1
Novartis
Phase 3 Completed